Intismeran autogene

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Oligonucleotide
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Oligonucleotide
www.ebi.ac.uk
Drug name
Intismeran autogene
www.ebi.ac.uk

  • intismeran autogen
  • Intismeran autogen
  • intismeran autogene
  • Intismeran autogene
  • Intismeran Autogene
  • intismeran autogene [INN]
  • INTISMERAN AUTOGENE [USAN]
  • Intismeran autogene [WHO-DD]
  • intismeran autogene inn
  • intismeran autogene usan
  • intismeran autogene who dd
  • messenger RNA (mRNA), 5'-capped, encoding a codon-optimized patient specific concatemer of up to 34 neoantigens designed specifically to each individual patient's tumor mutanome and human leukocyte antigen (HLA) type, further optimized by two additional stop codons, flanked by an artificial 5' untranslated region (UTR) and a 3' UTR derived from the human hemoglobin subunit alpha (HBA1) gene and terminated by a 3' polyadenylation (polyA) tail; contains N1-methylpseudouridine instead of uridine (all-U>m1Ψ)
  • messenger rna mrna 5 capped encoding a codon optimized patient specific concatemer of up to 34 neoantigens designed specifically to each individual patient s tumor mutanome and human leukocyte antigen hla type further optimized by two additional stop codons flanked by an artificial 5 untranslated region utr and a 3 utr derived from the human hemoglobin subunit alpha hba1 gene and terminated by a 3 polyadenylation polya tail contains n1 methylpseudouridine instead of uridine all u m1ψ
  • mrna 4157
  • mRNA-4157
  • mrna4157
  • MRNA4157
  • RNA (recombinant 5′-(m7G-(5′→5′)-ppp-Gm)-capped all uridine→N1-methylpseudouridine-substituted patient-specific neoantigen-specifying plus 5′- and 3′-untranslated flanking region-containing poly(A)-tailed messenger mRNA-4157), inner salt
  • rna recombinant 5 m7g 5 5 ppp gm capped all uridine n1 methylpseudouridine substituted patient specific neoantigen specifying plus 5 and 3 untranslated flanking region containing poly a tailed messenger mrna 4157 inner salt

CAS registry numbers
  • 2931460-85-2
ChEMBL ID
CHEMBL6068256
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • ZG6U44T8SG

First in class
No
Orphan designation
No

Drug name stem
-meran

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
    Highest recorded phase
    1
  • Condition identifier
    EFO_0000756
    Highest recorded phase
    3
  • Condition identifier
    EFO_1001927
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0001056
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0001187
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005012
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005086
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005105
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005184
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005549
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0040679
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

Related records

Trials (11)

In development for (2)